<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03220958</url>
  </required_header>
  <id_info>
    <org_study_id>2017-7898</org_study_id>
    <nct_id>NCT03220958</nct_id>
  </id_info>
  <brief_title>Metoclopramide for Post Traumatic Headache</brief_title>
  <official_title>A Randomized Placebo Controlled Trial of IV Metoclopramide for Acute Post-traumatic Headache</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Montefiore Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Montefiore Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Nearly 1.5 million patients present to US emergency departments annually following head&#xD;
      trauma. Headache is a frequent symptom of victims of head trauma. The purpose of this study&#xD;
      is to see if an intravenous medication called metoclopramide can improve the symptoms of&#xD;
      patients with acute post-traumatic headache.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 1, 2017</start_date>
  <completion_date type="Actual">April 1, 2020</completion_date>
  <primary_completion_date type="Actual">April 1, 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>0-10 Pain Scale on Which 0 = no Pain and 10= the Worst Pain Imaginable</measure>
    <time_frame>1 hour after medication administration</time_frame>
    <description>Improvement in this 0 to 10 verbal rating scale</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Sustained Headache Relief</measure>
    <time_frame>48 hours after medication administration</time_frame>
    <description>Achieving a headache intensity of mild or none in the ED without use of rescue medication and maintaining a level of mild or none. Participants rate their headache as none, mild, moderate, or severe</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Headache Days</measure>
    <time_frame>7 days after ED visit</time_frame>
    <description>Number of days with any headache. Participants report the actual number of days they experienced headache. A &quot;day&quot; begins when they awake for the beginning of daily activities and ends when they go to sleep after completion of daily activities</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">160</enrollment>
  <condition>Post-Traumatic Headache</condition>
  <arm_group>
    <arm_group_label>Metoclopramide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Metoclopramide 20mg + diphenhydramine 25mg + 100cc normal saline, administered as an intravenous drip</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Normal saline, administered as an intravenous drip</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metoclopramide</intervention_name>
    <description>Metoclopramide 20mg</description>
    <arm_group_label>Metoclopramide</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Diphenhydramine</intervention_name>
    <description>Diphenhydramine 25mg</description>
    <arm_group_label>Metoclopramide</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Normal saline</intervention_name>
    <description>100ml normal saline</description>
    <arm_group_label>Metoclopramide</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Included patients will be adults who meet International Classification of Headache&#xD;
        Disorders criteria for acute post-traumatic headache. These are as follows:&#xD;
&#xD;
          -  Traumatic injury to the head has occurred&#xD;
&#xD;
          -  Headache has developed within 7 days of injury to the head&#xD;
&#xD;
          -  Headache is not better accounted for by another diagnosis (eg, previous history of&#xD;
             migraine or tension-type headache)&#xD;
&#xD;
        The headache must be rated as moderate or severe in intensity at the time of initial&#xD;
        evaluation.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Patients will be excluded if more than ten days have elapsed since the head trauma, if the&#xD;
        headache has already been treated with an anti-dopaminergic medication, or for medication&#xD;
        contra-indications including pheochromocytoma, seizure disorder, Parkinson's disease, use&#xD;
        of MAO inhibitors, and use of anti-rejection transplant medications.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Montefiore Medical Center</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10467</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>April 19, 2017</study_first_submitted>
  <study_first_submitted_qc>July 15, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">July 18, 2017</study_first_posted>
  <results_first_submitted>July 13, 2021</results_first_submitted>
  <results_first_submitted_qc>November 8, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">November 9, 2021</results_first_posted>
  <last_update_submitted>November 8, 2021</last_update_submitted>
  <last_update_submitted_qc>November 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Montefiore Medical Center</investigator_affiliation>
    <investigator_full_name>Benjamin W. Friedman, MD</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Post-Traumatic Headache</mesh_term>
    <mesh_term>Headache</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diphenhydramine</mesh_term>
    <mesh_term>Promethazine</mesh_term>
    <mesh_term>Metoclopramide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>July 11, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/58/NCT03220958/Prot_SAP_002.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Metoclopramide</title>
          <description>Metoclopramide 20mg + diphenhydramine 25mg + 100cc normal saline, administered as an intravenous drip&#xD;
Metoclopramide: Metoclopramide 20mg&#xD;
Diphenhydramine: Diphenhydramine 25mg&#xD;
Normal saline: 100ml normal saline</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Normal saline, administered as an intravenous drip&#xD;
Normal saline: 100ml normal saline</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="81"/>
                <participants group_id="P2" count="79"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="81"/>
                <participants group_id="P2" count="79"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Metoclopramide</title>
          <description>Metoclopramide 20mg + diphenhydramine 25mg + 100cc normal saline, administered as an intravenous drip&#xD;
Metoclopramide: Metoclopramide 20mg&#xD;
Diphenhydramine: Diphenhydramine 25mg&#xD;
Normal saline: 100ml normal saline</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Normal saline, administered as an intravenous drip&#xD;
Normal saline: 100ml normal saline</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="81"/>
            <count group_id="B2" value="79"/>
            <count group_id="B3" value="160"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="81"/>
                    <count group_id="B2" value="79"/>
                    <count group_id="B3" value="160"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="43" spread="16"/>
                    <measurement group_id="B2" value="46" spread="17"/>
                    <measurement group_id="B3" value="45" spread="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="81"/>
                    <count group_id="B2" value="79"/>
                    <count group_id="B3" value="160"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="51"/>
                    <measurement group_id="B2" value="56"/>
                    <measurement group_id="B3" value="107"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="81"/>
                    <count group_id="B2" value="79"/>
                    <count group_id="B3" value="160"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="81"/>
                    <measurement group_id="B2" value="79"/>
                    <measurement group_id="B3" value="160"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline pain intensity, as measured on a 0-10 scale</title>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="81"/>
                    <count group_id="B2" value="79"/>
                    <count group_id="B3" value="160"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8.3" spread="1.6"/>
                    <measurement group_id="B2" value="8.3" spread="1.5"/>
                    <measurement group_id="B3" value="8.3" spread="1.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>0-10 Pain Scale on Which 0 = no Pain and 10= the Worst Pain Imaginable</title>
        <description>Improvement in this 0 to 10 verbal rating scale</description>
        <time_frame>1 hour after medication administration</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Metoclopramide</title>
            <description>Metoclopramide 20mg + diphenhydramine 25mg + 100cc normal saline, administered as an intravenous drip&#xD;
Metoclopramide: Metoclopramide 20mg&#xD;
Diphenhydramine: Diphenhydramine 25mg&#xD;
Normal saline: 100ml normal saline</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Normal saline, administered as an intravenous drip&#xD;
Normal saline: 100ml normal saline</description>
          </group>
        </group_list>
        <measure>
          <title>0-10 Pain Scale on Which 0 = no Pain and 10= the Worst Pain Imaginable</title>
          <description>Improvement in this 0 to 10 verbal rating scale</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="81"/>
                <count group_id="O2" value="79"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.2" spread="2.3"/>
                    <measurement group_id="O2" value="3.8" spread="2.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Sustained Headache Relief</title>
        <description>Achieving a headache intensity of mild or none in the ED without use of rescue medication and maintaining a level of mild or none. Participants rate their headache as none, mild, moderate, or severe</description>
        <time_frame>48 hours after medication administration</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Metoclopramide</title>
            <description>Metoclopramide 20mg + diphenhydramine 25mg + 100cc normal saline, administered as an intravenous drip&#xD;
Metoclopramide: Metoclopramide 20mg&#xD;
Diphenhydramine: Diphenhydramine 25mg&#xD;
Normal saline: 100ml normal saline</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Normal saline, administered as an intravenous drip&#xD;
Normal saline: 100ml normal saline</description>
          </group>
        </group_list>
        <measure>
          <title>Sustained Headache Relief</title>
          <description>Achieving a headache intensity of mild or none in the ED without use of rescue medication and maintaining a level of mild or none. Participants rate their headache as none, mild, moderate, or severe</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="78"/>
                <count group_id="O2" value="76"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24"/>
                    <measurement group_id="O2" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Headache Days</title>
        <description>Number of days with any headache. Participants report the actual number of days they experienced headache. A &quot;day&quot; begins when they awake for the beginning of daily activities and ends when they go to sleep after completion of daily activities</description>
        <time_frame>7 days after ED visit</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Metoclopramide</title>
            <description>Metoclopramide 20mg + diphenhydramine 25mg + 100cc normal saline, administered as an intravenous drip&#xD;
Metoclopramide: Metoclopramide 20mg&#xD;
Diphenhydramine: Diphenhydramine 25mg&#xD;
Normal saline: 100ml normal saline</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Normal saline, administered as an intravenous drip&#xD;
Normal saline: 100ml normal saline</description>
          </group>
        </group_list>
        <measure>
          <title>Headache Days</title>
          <description>Number of days with any headache. Participants report the actual number of days they experienced headache. A &quot;day&quot; begins when they awake for the beginning of daily activities and ends when they go to sleep after completion of daily activities</description>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="76"/>
                <count group_id="O2" value="71"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.3" spread="1.6"/>
                    <measurement group_id="O2" value="3.3" spread="1.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>48 hours</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Metoclopramide</title>
          <description>Metoclopramide 20mg + diphenhydramine 25mg + 100cc normal saline, administered as an intravenous drip&#xD;
Metoclopramide: Metoclopramide 20mg&#xD;
Diphenhydramine: Diphenhydramine 25mg&#xD;
Normal saline: 100ml normal saline</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Normal saline, administered as an intravenous drip&#xD;
Normal saline: 100ml normal saline</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="79"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>2</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="35" subjects_at_risk="81"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="79"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="81"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="79"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Various other</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="81"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="79"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Drowsiness</sub_title>
                <counts group_id="E1" events="15" subjects_affected="15" subjects_at_risk="81"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Akathisia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="81"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="81"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Post-concussive syndrome</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="81"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="79"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Benjamin Friedman</name_or_title>
      <organization>Montefiore</organization>
      <phone>718-920-6626</phone>
      <email>befriedm@montefiore.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

